Skip to content
Screener

West Pharmaceutical Services WST Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$20M0.0%
Cardinal Health, Inc. logo
Cardinal Health, Inc.CAH
500K0.0%
UFP Technologies logo
UFP TechnologiesUFPT
$1M
Charles River Laboratories logo
Charles River LaboratoriesCRL
$20M0.0%
Trimas logo
TrimasTRS

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$24.92B+43.4%
Enterprise value$24.8B+44.4%
P/E44.1×+8.5×
P/S7.5×+1.6×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000105770-26-000099
(in millions, except per share data)June 30,2026December 31,2025
Total Liabilities1,086.21,094.0
Commitments and contingencies (Note 16)
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: June 30, 2026 - 75.3 million, December 31, 2025 - 75.3 million; shares outstanding: June 30, 2026 - 70.4 million, December 31, 2025 - 72.0 million18.818.8
Capital in excess of par value
Retained earnings4,624.14,374.9
Accumulated other comprehensive loss(140.4)(105.5)

Item 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is West Pharmaceutical Services's preferred stock, shares authorized?
West Pharmaceutical Services (WST) reported preferred stock, shares authorized of $3M in Q2 2026.
How has West Pharmaceutical Services's preferred stock, shares authorized changed year-over-year?
West Pharmaceutical Services's preferred stock, shares authorized decreased by 0.0% year-over-year, from $3M to $3M.
What is the long-term trend for West Pharmaceutical Services's preferred stock, shares authorized?
Over 5 years (2020 to 2025), West Pharmaceutical Services's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $3M to $3M.

Ask your AI about West Pharmaceutical Services's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude